Rademikibart 'Could Be Incredibly Important for Type 2'

A second-generation IL-4Rα inhibitor known as rademikibart shows promise for further elevating the standard of care for type 2 inflammatory conditions in the future, Dr. Christopher Bunick said during a presentation at the 44th Annual Fall Clinical Dermatology Conference.

Dr. Bunick showed how rademikibart’s mechanism of action differs from first-generation biologics such as dupilumab, lebrikizumab, and tralokinumab during the presentation “Systemic Therapies for Inflammatory Skin Diseases: How to Choose Between Monoclonal Antibodies, JAK Inhibitors and Other Therapies,” which he presented alongside Drs. April W. Armstrong, Emma Gutman-Yassky, and Elizabeth (Lisa) Swanson.

“Rademikibart has an optimized epitope on IL-4Rα, which gives it a twofold higher binding affinity than dupilumab,” Dr. Bunick told Practical Dermatology. “This has translated into some really good phase 2 atopic dermatitis data in clinical trials in China. Here in the US, studies have focused on asthma, for which rademikibart has shown tremendous rapid effect and a higher safety profile than dupilumab. This could be incredibly important for type 2 inflammatory diseases.”